Search Results for "vaccine, adult"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, adult. Results 251 to 260 of 293 total matches.
See also: MMR II
Tapinarof Cream (Vtama) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
(AhR) agonist tapinarof, for treatment of adults with
plaque psoriasis. It is the first AhR agonist ...
The FDA has approved Vtama (Dermavant), a 1%
cream formulation of the aryl hydrocarbon receptor
(AhR) agonist tapinarof, for treatment of adults with
plaque psoriasis. It is the first AhR agonist to be
approved by the FDA.
An EUA for Bebtelovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
the emergence of the Omicron variant.
In one cohort, 380 unvaccinated, mostly low-risk
adults were randomized ...
The investigational monoclonal antibody
bebtelovimab (LY-CoV1404 – Lilly) has been granted
an FDA Emergency Use Authorization (EUA) for IV
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death, and for whom alternative
treatment options are unavailable or inappropriate.
Bebtelovimab is active against the Omicron variant of
SARS-CoV-2; sotrovimab (VIR-7831) is the only other
monoclonal antibody currently available for treatment
of COVID-19 that is active...
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
years (estimated prevalence
40 cases per 100,000 persons).2 EoE is thought
to be an abnormal immune ...
Eohilia (Takeda), an oral suspension formulation of
the corticosteroid budesonide, has been approved
by the FDA for treatment of eosinophilic esophagitis
(EoE) in patients ≥11 years old. It is the first oral
drug to be approved in the US for this indication. The
subcutaneously injected interleukin (IL)-4 receptor
antagonist dupilumab (Dupixent) is approved
for treatment of EoE in patients ≥1 year old who
weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5 doi:10.58347/tml.2024.1704c | Show Introduction Hide Introduction
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
to severe ulcerative colitis or Crohn’s
disease in adults who have not responded to, lost
response ...
The FDA has approved vedolizumab (Entyvio - Takeda),
an intravenous integrin receptor antagonist, for treatment
of moderate to severe ulcerative colitis or Crohn's
disease in adults who have not responded to, lost
response to, or cannot tolerate standard treatment.
Natalizumab (Tysabri), another integrin receptor antagonist,
has been available for several years for treatment
of Crohn's disease and multiple sclerosis.
Monoclonal For Gram-Negative Sepsis
The Medical Letter on Drugs and Therapeutics • Nov 01, 1991 (Issue 856)
). Human J5 immune plasma also protected against gram-negative shock and
death when given prophylactically ...
HA-1A (Centoxin - Centocor), a monoclonal IgM antibody against endotoxin from gram-negative bacteria, may soon be approved for marketing by the US Food and Drug Administration. Commercially available in Europe, HA-1A has been used in the USA as an investigational drug. E5 (Xomen - Xoma), another monoclonal IgM antibody against endotoxin, is also available here for investigational use.
Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
on the results of an open-label
trial in 155 adults with relapsed or refractory DLBCL,
not otherwise specified ...
Glofitamab-gxbm (Columvi – Genentech), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for IV treatment of
relapsed or refractory diffuse large B-cell lymphoma
(DLBCL), not otherwise specified, or large B-cell
lymphoma (LBCL) arising from follicular lymphoma
after ≥2 lines of systemic therapy. Accelerated
approval was based on response rates and durability
of response. Glofitamab is the second T-cell-engaging
bispecific antibody to be approved in the US
for treatment of DLBCL; epcoritamab-bysp (Epkinly),
which is given...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e129-30 doi:10.58347/tml.2023.1682b | Show Introduction Hide Introduction
Biktarvy - Another INSTI-Based Combination for HIV
The Medical Letter on Drugs and Therapeutics • Aug 13, 2018 (Issue 1553)
), for treatment of HIV-1
infection in adults. The new combination is indicated for
use in patients who ...
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide (TAF), for treatment of HIV-1
infection in adults. The new combination is indicated for
use in patients who are antiretroviral-naive or who have
been virologically suppressed on a stable antiretroviral
regimen for ≥3 months with no history of treatment
failure and no known substitutions associated with
resistance to any component of the...
Dupilumab (Dupixent) for Asthma
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
-dependent asthma. Dupilumab was
approved earlier to treat adults with moderate to
severe atopic dermatitis ...
The FDA has approved the subcutaneously injected
monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of
patients ≥12 years old with moderate to severe
asthma with an eosinophilic phenotype or with oral
corticosteroid-dependent asthma. Dupilumab was
approved earlier to treat adults with moderate to
severe atopic dermatitis inadequately controlled with
topical therapies.
Voclosporin (Lupkynis) for Lupus Nephritis
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
mofetil (Cellcept, and
generics) and a corticosteroid for treatment of adults
with active lupus ...
Voclosporin (Lupkynis – Aurinia), an oral calcineurin
inhibitor, has been approved by the FDA for use
in combination with the antimetabolite immunosuppressant
mycophenolate mofetil (Cellcept, and
generics) and a corticosteroid for treatment of adults
with active lupus nephritis. It is the first calcineurin
inhibitor to be approved in the US for this indication.
Tacrolimus (Prograf, and others) and cyclosporine
(Neoral, and others), the other available systemic
calcineurin inhibitors, are approved for prophylaxis of
organ rejection in transplant patients.
Statins and Diabetes Risk
The Medical Letter on Drugs and Therapeutics • Sep 01, 2014 (Issue 1450)
an immune
response that interferes with insulin signaling.2
NEW-ONSET DIABETES RISK — A meta-analysis ...
In 2012, the FDA required manufacturers of HMG-CoA
reductase inhibitors (statins) to add a warning to their
labels about reports of increased blood glucose and
glycosylated hemoglobin (HbA1c) levels. Since then,
several new studies have been published.